• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix.

作者信息

Eifel P J, Morris M, Wharton J T, Oswald M J

机构信息

Division of Radiotherapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.

出版信息

Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16. doi: 10.1016/0360-3016(94)90220-8.

DOI:10.1016/0360-3016(94)90220-8
PMID:8175451
Abstract

PURPOSE

To define the influence of tumor size and morphology on rates of central tumor control (CTC), pelvic tumor control (PTC), and disease-specific survival (DSS) in patients treated with radiotherapy for squamous cell carcinoma of the intact uterine cervix.

METHODS AND MATERIALS

Records of 1526 patients treated with radiotherapy for FIGO Stage IB squamous cell carcinoma of the intact uterine cervix between 1960 and 1989 were retrospectively reviewed. The maximum tumor or cervical diameter was determined from clinical descriptions for 1494 patients. Tumors were divided into nine size categories. Tumors > or = 4 cm were further classified according to the dominant morphology (i.e., exophytic or endocervical). Median follow-up was 12.2 years. Five-year CTC, PTC, and DSS rates were calculated actuarially.

RESULTS

CTC, PTC, and DSS rates correlated strongly with tumor diameter (p < 0.0001). Overall, CTC, PTC, and DSS rates for patients with tumors < 5 cm were 99%, 97%, and 88%, respectively. For patients with tumors 5-7.9 cm these rates were 93%, 84%, and 69%, respectively. There were no significant differences in the rates of PTC, CTC, or DSS between subgroups of patients with lesions 5-7.9 cm in diameter. The rates of CTC (97%) and DSS (76%) for patients with 5-7.9 cm exophytic tumors were significantly better than those for patients with endocervical tumors of the same size (91% and 66%, respectively); there was no difference in the PTC rate.

CONCLUSION

Although the CTC rates were excellent for all patients with tumors < 8 cm in diameter, these rates for tumors < 5 cm (99%) and for exophytic tumors 5-7.9 cm (97%) make it difficult to justify the use of adjuvant hysterectomy. Although patients with tumors of 5-7.9 cm had consistently poorer PTC and DSS rates than did patients with smaller tumors, the control rates achieved with aggressive radiotherapy were still excellent. The strong correlation between tumor size and outcome suggests that tumor diameter should be assessed when tumors are clinically evaluated and staged and when treatment results are reported for patients with FIGO Stage IB carcinoma of the uterine cervix.

摘要

相似文献

1
The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix.
Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16. doi: 10.1016/0360-3016(94)90220-8.
2
Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy.FIGO IIIB期宫颈鳞状细胞癌:强调外照射与腔内放射治疗平衡的预后因素分析
Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):763-75. doi: 10.1016/s0360-3016(98)00482-9.
3
Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma.腺癌是IB期宫颈癌患者疾病复发的独立危险因素。
Gynecol Oncol. 1995 Oct;59(1):38-44. doi: 10.1006/gyno.1995.1265.
4
Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix.子宫颈癌的肿瘤大小、放射剂量及长期预后
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):307-17. doi: 10.1016/s0360-3016(98)00067-4.
5
Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery.肿瘤大小对术前放疗及手术治疗的子宫颈癌IB期和IIA期预后无影响。
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):645-51. doi: 10.1016/s0360-3016(99)00217-5.
6
Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors.单纯放疗治疗原位子宫颈癌:一项法国合作研究:预后因素的更新与多因素分析
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):969-78. doi: 10.1016/s0360-3016(97)00145-4.
7
Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy.接受体外照射和铱-192高剂量率近距离放射治疗的子宫颈癌患者的预后因素
Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):531-40. doi: 10.1016/s0360-3016(98)00255-7.
8
Bulky, barrel-shaped cervical carcinoma (stages IB, IIA, IIB): the prognostic factors for pelvic control and treatment outcome.巨大桶状宫颈癌(IB期、IIA期、IIB期):盆腔控制及治疗结果的预后因素
Am J Clin Oncol. 1999 Jun;22(3):232-6. doi: 10.1097/00000421-199906000-00004.
9
Residual disease in the uterus after preoperative radiotherapy and hysterectomy in stage IB cervical carcinoma.
Am J Clin Oncol. 1996 Oct;19(5):433-8. doi: 10.1097/00000421-199610000-00001.
10
Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy.子宫颈癌。I. 总治疗时间延长及近距离放疗时机对放射治疗结局的影响。
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88. doi: 10.1016/0360-3016(95)00220-S.

引用本文的文献

1
Stereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits.射波刀立体定向体部放射治疗对局部晚期宫颈癌的剂量分析及潜在临床获益
Cancers (Basel). 2022 Oct 21;14(20):5166. doi: 10.3390/cancers14205166.
2
Radical surgery for stage IB2/IIA2 cervical cancer: A large retrospective study.IB2/IIA2期宫颈癌的根治性手术:一项大型回顾性研究。
Front Oncol. 2022 Sep 23;12:948298. doi: 10.3389/fonc.2022.948298. eCollection 2022.
3
Relative clinical utility of simultaneous F-fluorodeoxyglucose PET/MRI and PET/CT for preoperative cervical cancer diagnosis.
同步 F-氟代脱氧葡萄糖 PET/MRI 和 PET/CT 在术前宫颈癌诊断中的相对临床效用。
J Int Med Res. 2021 Jun;49(6):3000605211019190. doi: 10.1177/03000605211019190.
4
Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?T2-4aN0M0 期膀胱癌的三联疗法——如何选择最佳患者?
Cancer Med. 2020 Nov;9(22):8491-8497. doi: 10.1002/cam4.3478. Epub 2020 Sep 22.
5
Clinical efficacy and prognostic factors of CT-guided I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes.CT 引导下 I 粒子近距离放疗治疗腹膜后转移性淋巴结姑息性治疗的临床疗效及预后因素分析。
Cancer Imaging. 2020 Apr 6;20(1):25. doi: 10.1186/s40644-020-00299-x.
6
Primary radical hysterectomy vs chemoradiation for IB2-IIA cervical cancer: A systematic review and meta-analysis.IB2-IIA期宫颈癌的根治性子宫切除术与放化疗对比:一项系统评价与荟萃分析
Medicine (Baltimore). 2020 Jan;99(5):e18738. doi: 10.1097/MD.0000000000018738.
7
Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix.新辅助化疗后行根治性放化疗与单纯根治性放化疗治疗局部晚期宫颈癌的对比研究
J Obstet Gynaecol India. 2019 Dec;69(6):546-552. doi: 10.1007/s13224-019-01236-0. Epub 2019 Jul 13.
8
Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.磁共振成像上的肿瘤生长模式与根治性放疗治疗局部晚期宫颈癌患者的治疗结局。
Int J Clin Oncol. 2019 Sep;24(9):1119-1128. doi: 10.1007/s10147-019-01457-3. Epub 2019 May 11.
9
Efficacy and Toxicity of IMRT-Based Simultaneous Integrated Boost for the Definitive Management of Positive Lymph Nodes in Patients with Cervical Cancer.基于调强放疗的同步整合加量在宫颈癌阳性淋巴结根治性治疗中的疗效与毒性
J Cancer. 2019 Jan 29;10(5):1103-1109. doi: 10.7150/jca.29301. eCollection 2019.
10
Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.根治性放化疗后宫颈鳞癌患者 SCC-Ag 水平升高对肿瘤复发和患者生存的意义:多中心分析。
J Gynecol Oncol. 2019 Jan;30(1):e1. doi: 10.3802/jgo.2019.30.e1. Epub 2018 Apr 30.